Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Too Fast, Too Much? Japan Cuts Prices By 6.7% As Annual Revisions Bite

Vyndaqel Slashed By 75%

Executive Summary

The Japanese government will apply new drug reimbursement prices from 1 April, under which Pfizer’s Vyndaqel will be slashed by 75% and UCB's E Keppra by 26%. Nobelpharma and Santen will be also affected by the revision, which averages close to 7% across the board.

You may also be interested in...



Some Uncertainty Ahead For Towa Following Strong Financial Year

Towa performed well during the financial year ended 31 March, delivering a ¥15.9bn profit, but questions remain about the impact of Japan’s NHI drug price revision and its acquisition of Sunsho Pharmaceuticals going forward.

Fear of Unpredictability: Industry Criticises Japan’s Frequent Pricing Rule Changes

While Japan enters annual drug price revisions with frequent regulation changes, several major corporate players in the country warn again that government policies mean that the country is at risk of “losing attractiveness.”

What’s Next? Five Things To Look Out For In April

In the month ahead, Japanese firms are set to be hit with further price cuts to their generics, while Eagle Pharmaceuticals will throw off the restraints for its Pemfexy (pemetrexed) 505(b)(2) version of Eli Lilly’s Alimta.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS145942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel